Privia Health Group, Inc. (NASDAQ: PRVA) Executive Vice President and Chief Financial Officer David Mountcastle has executed a sale of company stock, disposing of 24,734 shares on July 2, 2026. The total value of these transactions reached approximately $680,185. The shares were liquidated in multiple transactions at prices ranging from $27.50 to $27.51 per share, resulting in a weighted average price of $27.50. This timing is particularly notable given that Privia Health Group's stock was trading near its 52-week high of $27.52 at the time, with the stock price having climbed 27% over the preceding year.
These sales were conducted pursuant to a Rule 10b5-1 trading plan previously adopted by Mountcastle. Following the completion of these transactions, Mountcastle directly holds 186,728 shares of Privia Health Group common stock. Additionally, an extra 8,695 shares are held indirectly by his spouse. The sale occurs in the context of the company's recently reported first-quarter 2026 earnings, which presented a mixed financial picture. Privia Health Group reported an earnings per share (EPS) of $0.02, falling short of the anticipated $0.0746. However, revenue came in at $603.85 million, exceeding the projected $559.49 million by 7.93%.
Concurrently, Privia Health Group held its 2026 Annual Meeting of Stockholders, where shareholders approved all proposals. This included the election of three Class I directors: Nancy Cocozza, David King, and Francis Soistman, who will serve until the 2029 Annual Meeting. Cocozza received 103,661,977 votes in favor, King garnered 99,267,027 votes, and Soistman secured 105,602,389 votes. There were also 11,549,510 broker non-votes for each nominee. These developments highlight the company's ongoing strategic decisions and financial outcomes.